IP Library Granted Patent US 9,216,199
Granted Patent B2
US 9,216,199 · App. 14/562,650 · Granted Dec 22, 2015

Nutritional supplement containing phospholipid-DHA derived from eggs

Inventor: Rhett Sean Daniels (Fort Myers, FL)
Assignee: Buriva, LLC
A61K33/26A23L1/302A23L1/303A23L1/304A23L1/3008A61K31/198A61K31/341A61K31/4415A61K31/519A61K31/592A61K31/593A61K31/685A61K33/06A61K33/18A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,216,199
App. No.
14/562,650
Granted
Dec 22, 2015
Kind
B2
Abstract

Described herein are manufactured dietary supplements that contain a phospholipid extract derived from eggs, where the extract contains phospholipid-docosahexaenoic acid derived from eggs, folate, vitamin D, vitamin B6, vitamin B12, vitamin C, calcium, iron, N-Acetyl-L-Cysteine, iodine, and magnesium. Described herein are manufactured dietary supplements that contain a phospholipid extract derived from eggs and the extract contains two forms of phospholipid-docosahexaenoic acid derived from eggs. One form of phospholipid-docosahexaenoic acid is phosphatidylcholine-docosahexaenoic acid, and another form of phospholipid-docosahexaenoic acid is phosphatidylethanolamine-docosahexaenoic acid. And the phospholipid extract has less than about 3 % by weight of free triglycerides.

Claims (53)

1. A manufactured dietary supplement, comprising:

a phospholipid extract at a concentration ranging from 50 mg to 200 mg, the phospholipid extract having phosphatidylcholine-docosahexaenoic acid and phosphatidylethanolamine-docosahexaenoic acid at a ratio ranging from about 1:1 to 2:1, wherein the amount of phosphatidylcholine-docosahexaenoic acid comprises from about 7.5% to about 10% the amount of phospholipids in the supplement,

a pharmaceutically acceptable form of total folate,

a pharmaceutically acceptable form of Vitamin D,

a pharmaceutically acceptable form of Vitamin B 6 ,

a pharmaceutically acceptable form of Vitamin B 12 ,

a pharmaceutically acceptable form of Vitamin C,

a pharmaceutically acceptable form of Calcium,

a pharmaceutically acceptable form of Iron,

a pharmaceutically acceptable form of Iodine, and

a pharmaceutically acceptable form of Magnesium.

2. The manufactured dietary supplement of claim 1 , wherein the dietary supplement comprises:

the phospholipid extract derived from eggs at the concentration ranging from 50 mg to 200 mg, the phospholipid extract having phosphatidylcholine-docosahexaenoic acid and phosphatidylethanolamine-docosahexaenoic c acid at the ratio ranging from about 1:1 to about 2:1, the amount of phosphatidylcholine-docosahexaenoic acid ranging between from about 5 mg to about 20 mg

the pharmaceutically acceptable form of total folate is between about 400 mcg and about 1 mg,

the pharmaceutically acceptable form of Vitamin D is between about 1000 IU and about 1500 IU,

the pharmaceutically acceptable form of Vitamin B 6 is between about 26 mg and about 30 mg,

the pharmaceutically acceptable form of Vitamin B 12 is between about 12 mcg and about 20 mcg,

the pharmaceutically acceptable form of Vitamin C is between about 70 mg and about 100 mg,

the pharmaceutically acceptable form of Calcium is between about 15 mg and about 20 mg,

the pharmaceutically acceptable form of Iron is between about 5 mg and about 30 mg, the pharmaceutically acceptable form of Iodine is between about 150 mcg and about 200 mcg, and

the pharmaceutically acceptable form of Magnesium is between about 5 mg and about 20 mg.

3. The manufactured dietary supplement of claim 1 , wherein the amount of phosphatidylcholine-docosahexaenoic acid in the supplement is between about 5 mg and about 20 mg.

4. The manufactured dietary supplement of claim 1 , wherein the amount of phosphatidylethanolamine-docosahexaenoic acid in the supplement is between about 5 mg and about 20 mg.

5. The manufactured dietary supplement of claim 1 , wherein the phospholipid extract is not derived from a genetically modified organism.

6. The manufactured dietary supplement of claim 1 , wherein the phospholipid extract contains less than 5% free triglycerides.

7. The manufactured dietary supplement of claim 1 , wherein at least about 8% phospholipid extract is phosphatidylethanolamine-docosahexaenoic acid.

8. The manufactured dietary supplement of claim 1 , wherein the manufactured dietary supplement is a capsule or softgel.

9. The manufactured dietary supplement of claim 1 , wherein the pharmaceutically acceptable form of total folate comprises more than one form of folate.

10. The manufactured dietary supplement of claim 1 , wherein the amount of phosphatidylcholine-docosahexaenoic acid in the supplement is about 20 mg, and the amount of phosphatidylethanolamine-docosahexaenoic acid in the supplement is about 20 mg.

11. A method of providing prenatal and postnatal nutrition to a mother, the method comprising:

selecting a woman,

administering a manufactured dietary supplement, comprising:

a phospholipid extract derived from eggs at a concentration ranging from 50 mg to 200 mg, the phospholipid extract having phosphatidylcholine-docosahexaenoic acid and phosphatidylethanolamine-docosahexaenoic acid at a ratio ranging from 1:1 to 5:1,

a pharmaceutically acceptable form of total folate,

a pharmaceutically acceptable form of Vitamin D,

a pharmaceutically acceptable form of Vitamin B 6 ,

a pharmaceutically acceptable form of Vitamin B 12 ,

a pharmaceutically acceptable form of Vitamin C,

a pharmaceutically acceptable form of Calcium,

a pharmaceutically acceptable form of Iron,

a pharmaceutically acceptable form of Iodine, and

a pharmaceutically acceptable form of Magnesium.

12. The method of claim 11 , wherein

the amount of phosphatidylcholine-docosahexaenoic acid ranges between from about 5 mg to about 20 mg and the amount of phosphatidylethanolamine-docosahexaenoic acid ranges between from about 5 mg to about 20 mg,

the amount of total folate is between about 400 mcg and about 1 mg, wherein the amount of total folate is from more than one source of folate,

the pharmaceutically acceptable form of Vitamin D is between about 1000 IU and about 1500 IU,

the pharmaceutically acceptable form of Vitamin B 6 is between about 26 mg and about 30 mg,

the pharmaceutically acceptable form of Vitamin B 12 is between about 12 mcg and about 20 mcg,

the pharmaceutically acceptable form of Vitamin C is between about 70 mg and about 100 mg,

the pharmaceutically acceptable form of Calcium is between about 15 mg and about 20 mg,

the pharmaceutically acceptable form of Iron is between about 5 mg and about 30 mg,

the pharmaceutically acceptable form of Iodine is between about 150 mcg and about 200 mcg, and

the pharmaceutically acceptable form of Magnesium is between about 5 mg and about 20 mg.

Assignments (3)
SECURITY INTEREST Recorded Nov 11, 2016
From: VERTICAL PHARMACEUTICALS, LLC
To: CIT BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040290/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2016
From: BURIVA, LLC
To: VERTICAL PHARMACEUTICALS, LLC
Reel/Frame 039834/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: DANIELS, RHETT SEAN
To: BURIVA, LLC
Reel/Frame 039779/0374 →
Continuity (3)
Provisional Application 61912205 · Dec 5, 2013
Provisional Application 62088528 · Dec 5, 2014
Related Publication 20150174164A1 · Jun 25, 2015